Riskpilot← Back to searchSign inGet full accessJ&K Medkonsult AB
ABActiveOrg 5592533854Blomstervägen 4Medical specialists activities · NACE 8622Est. 20201 employees
Revenue 2024
SEK 657K
-3% vs 2023
EBITDA margin
57.2%
-3% vs 2023
Equity ratio
49.0%
Financial strength
Net profit 2024
SEK 407K
+51% vs 2023
| Revenue | SEK 657K | -3% |
| EBITDA | SEK 376K | -3% |
| Net profit | SEK 407K | +51% |
| Total assets | SEK 893K | +11% |
| Equity | SEK 438K | -22% |
| Employees | 1 | — |
Legal name
J&K Medkonsult AB
Org number
5592533854
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
23 april 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Medicinsk och kirurgisk specialistvård och konsultverksamhet inom hälso och sjukvård, läkarbemanning och därtill förenlig verksamhet samt handel med värdepapper.
Address
Blomstervägen 4
Email
jkmedkonsultab@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 331 | 547 | 577 | 680 | 657 |
| Staff expenses | — | — | −36 | −26 | −26 |
| EBITDA | 188 | 118 | 284 | 390 | 376 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 188 | 118 | 284 | 390 | 376 |
| Net financials | — | −2 | −0 | −39 | 136 |
| Profit before tax | 188 | 116 | 284 | 351 | 513 |
| Tax | −36 | −28 | −59 | −80 | −106 |
| Net profit | 152 | 88 | 226 | 270 | 407 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 313 | 389 | 648 | 804 | 893 |
| Equity | 177 | 265 | 491 | 561 | 438 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 136 | 123 | 157 | 243 | 455 |
| Total debt | 136 | 123 | 157 | 243 | 455 |
EBITDA margin
57.2%
This company
15.8%
Market median
+262% vs market
20202024
Equity ratio
49.0%
This company
38.2%
Market median
+28% vs market
20202024
Return on equity
93.0%
This company
18.4%
Market median
+405% vs market
20202024
Net profit margin
61.9%
This company
8.1%
Market median
+664% vs market
20202024
Asset turnover
0.74×
This company
1.12×
Market median
-34% vs market
20202024
Debt / equity
1.04×
This company
0.62×
Market median
-68% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-04-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
J&K Medkonsult AB 
Skövde Specialistläkare ABBoard members of J&K Medkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Joakim Palmquist | Board of Directors | 0 companies |
| Kristin Beyer | Deputy Board Member | 0 companies |